Palatin Technologies (PTN) Shares Gap Down to $0.95

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) gapped down prior to trading on Thursday . The stock had previously closed at $0.97, but opened at $0.95. Palatin Technologies shares last traded at $0.90, with a volume of 2189400 shares trading hands.

PTN has been the topic of several analyst reports. Canaccord Genuity set a $6.00 price target on shares of Palatin Technologies and gave the stock a “buy” rating in a research report on Monday, November 13th. Zacks Investment Research raised shares of Palatin Technologies from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research report on Thursday, October 5th. Finally, Roth Capital set a $2.00 price target on shares of Palatin Technologies and gave the stock a “buy” rating in a research report on Sunday, October 29th.

Palatin Technologies (NYSEAMERICAN:PTN) last announced its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.01). The company had revenue of $26.94 million for the quarter, compared to analyst estimates of $28.00 million. During the same quarter in the prior year, the business posted ($0.08) EPS.

An institutional investor recently raised its position in Palatin Technologies stock. Bank of New York Mellon Corp raised its holdings in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) by 500.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 151,473 shares of the biopharmaceutical company’s stock after purchasing an additional 126,236 shares during the period. Bank of New York Mellon Corp owned approximately 0.08% of Palatin Technologies worth $101,000 at the end of the most recent quarter.

TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at

Palatin Technologies Company Profile

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

What are top analysts saying about Palatin Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Palatin Technologies Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit